Velocity Financial, Inc. (VEL) Q1 2026 Earnings Call Transcript
Velocity Financial, Inc. (VEL) Q1 2026 Earnings Call Transcript
VEL - Velocity Financial, Inc.
Price:
--
--
|
CONSENSUS:
Buy
DETAILS
|
PRICE TARGET:
$23.00
DETAILS
HIGH:
$23.00
LOW:
$23.00
MEDIAN:
$23.00
CONSENSUS:
$23.00
UPSIDE:
33.95%
Stock News
Velocity Financial, Inc. Reports First Quarter 2026 Results
WESTLAKE VILLAGE, Calif.--(BUSINESS WIRE)--Velocity Financial, Inc. (NYSE: VEL) (Velocity or the Company), a leader in business purpose loans, reported net income of $22.4 million and core net income of $26.5 million for 1Q26, compared to $18.9 million and $20.3 million, respectively, for 1Q25. Earnings and core earnings per diluted share were $0.57 and $0.68 for 1Q26, compared to $0.51 and $0.55, respectively, for 1Q25. “Velocity continued to deliver impressive earnings in the first quarter of.
OSE Immunotherapeutics Welcomes FDA Orphan Drug Designation Granted to Pegrizeprument (VEL-101) for Prevention of Organ Rejection in Heart Transplant Patients
Nantes, France, April 27, 2026 – 7:30am CEST - OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnemo: OSE), today welcomes the announcement by its partner Veloxis Pharmaceuticals, Inc. that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation to pegrizeprument (VEL‑101) for the prophylaxis of heart allograft rejection in patients receiving a heart transplant. This follows the recent ODD granted in January 2026 for prevention of organ rejection in patients receiving a liver transplant.
Velocity Financial, Inc. Announces Date of First Quarter 2026 Financial Results Webcast and Conference Call
WESTLAKE VILLAGE, Calif.--(BUSINESS WIRE)--Velocity Financial, Inc. (NYSE:VEL) (“Velocity” or “Company”), a leader in investor real estate loans, will release its first quarter 2026 results after the market close on Wednesday, May 6, 2026. Velocity's executive management team will host a conference call and webcast to review its financial results at 2:00 p.m. Pacific Time / 5:00 p.m. Eastern Time on the same day. Webcast Information The conference call will be webcast live in listen-only mode a.
Velocity Financial, Inc. (VEL) Q4 2025 Earnings Call Transcript
Velocity Financial, Inc. (VEL) Q4 2025 Earnings Call Transcript
Velocity Financial, Inc. Reports Fourth Quarter and Full-Year 2025 Results
WESTLAKE VILLAGE, Calif.--(BUSINESS WIRE)--Velocity Financial, Inc. (NYSE: VEL) (Velocity or the Company), a leader in business purpose loans, reported net income of $105.1 million and core net income of $111.0 million for 2025, compared to $68.4 million and $72.9 million, respectively, for 2024. Earnings and core earnings per diluted share were $2.75 and $2.91 for 2025, compared to $1.91 and $2.03, respectively, for 2024. “Velocity delivered impressive earnings in the fourth quarter and full y.
Velocity Financial, Inc. Announces Closing of Offering of $500 Million of Senior Notes Due 2031
WESTLAKE VILLAGE, Calif.--(BUSINESS WIRE)--Velocity Financial, Inc. (NYSE: VEL) (“Velocity” or the “Company”), a leader in investor real estate loans, today announced the closing of Velocity Commercial Capital, LLC's, a wholly-owned subsidiary of Velocity (the “Issuer”), previously announced offering of $500 million aggregate principal amount of 9.375% Senior Notes due 2031 (the “Notes”) which was sold at an offering price equal to 100% of the principal thereof in an offering exempt from regist.
Velocity Financial, Inc. Announces Date of Fourth Quarter and Full Year 2025 Financial Results Webcast and Conference Call
WESTLAKE VILLAGE, Calif.--(BUSINESS WIRE)--Velocity Financial, Inc. (NYSE:VEL) (“Velocity” or “Company”), a leader in investor real estate loans, will release its fourth quarter and full year 2025 results after the market close on Wednesday, March 11, 2026. Velocity's executive management team will host a conference call and webcast to review its financial results at 2:00 p.m. Pacific Time / 5:00 p.m. Eastern Time on the same day. Webcast Information The conference call will be webcast live in.
Velocity Financial, Inc. Announces Pricing of $500 Million of Senior Notes Due 2031
WESTLAKE VILLAGE, Calif.--(BUSINESS WIRE)--Velocity Financial, Inc. (NYSE: VEL) (“Velocity” or the “Company”), a leader in investor real estate loans, today announced that Velocity Commercial Capital, LLC, a wholly-owned subsidiary of Velocity (the “Issuer”), priced $500 million aggregate principal amount of 9.375% Senior Notes due 2031 (the “Notes”) at an offering price equal to 100% of the principal thereof, to be sold in an offering exempt from registration under the Securities Act of 1933,.
Velocity Financial, Inc. Announces Proposed Offering of $500 Million of Senior Notes Due 2031
WESTLAKE VILLAGE, Calif.--(BUSINESS WIRE)--Velocity Financial, Inc. (NYSE: VEL), (“Velocity” or the “Company”), a leader in investor real estate loans, today announced that Velocity Commercial Capital, LLC, a wholly-owned subsidiary of Velocity (the “Issuer”), plans to offer up to $500 million aggregate principal amount of Senior Notes due 2031 (the “Notes”) to be sold in an offering exempt from registration under the Securities Act of 1933, as amended (the “Securities Act”) to individuals reas.
Velocity Financial, Inc. Announces Preliminary Expected Fourth Quarter and Full-Year 2025 Results
WESTLAKE VILLAGE, Calif.--(BUSINESS WIRE)--Velocity Financial, Inc. (NYSE:VEL) (“Velocity” or “Company”), a leader in investor real estate loans, today announced preliminary unaudited results for the fourth quarter and full-year 2025. Fourth Quarter 2025 preliminary expected unaudited results For the three-month period ended December 31, 2025, as compared to the same period of 2024: Net income of at least $35 million, an increase of at least 70% GAAP earnings per diluted common share of at leas.
OSE Immunotherapeutics Welcomes FDA Orphan Drug Designation Granted to Pegrizeprument (VEL-101)
OSE Immunotherapeutics Welcomes FDA Orphan Drug Designation Granted to Pegrizeprument (VEL-101) Nantes, France, January 21, 2026 – 6pm CET - OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnemo: OSE), today acknowledges the announcement by its partner Veloxis Pharmaceuticals, Inc. that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation to pegrizeprument (VEL-101) for the prevention of organ rejection in patients undergoing liver transplantation. Veloxis' full press release is available here.